助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   期临床 的翻译结果: 查询用时:0.1秒
图标索引 在分类学科中查询
所有学科
肿瘤学
更多类别查询

图标索引 历史查询
 

期临床
相关语句
  clinical phase
     Clinical Phase II Study on Immunoimprovement of Patients with Breast Cancer Treated by Shenyi Capsule
     参一胶囊对乳腺癌化疗患者免疫扶正Ⅱ期临床研究
短句来源
     Objective To investigate the radiosensitizing effect and clinical safety of sodium glycididazole (CMNa) in a randomized double blind clinical Phase Ⅱ study.
     目的 对针剂甘氨双唑钠 (CMNa)的放射治疗增敏作用及临床安全性进行随机、双盲Ⅱ期临床研究。
短句来源
     Clinical Phase II Trial of a New Antineopiastlc Drug - Glyciphosphoramide
     新抗肿瘤药甘磷酰芥二期临床试用总结
短句来源
     Clinical phase Ⅱstudy on concurrent hyperfractionated radiotherapy and NP chemotherapy for locally advanced non-small cell lung cancer
     超分割放疗同步NP方案化疗局部晚期非小细胞肺癌的Ⅱ期临床研究
短句来源
     RESULT OF A CLINICAL PHASE Ⅱ TRIAL OF MABTHERA IN 30 CHINESE B CELL LYMPHOMAS PATIENTS
     美罗华治疗B细胞淋巴瘤Ⅱ期临床验证报告
短句来源
更多       
  “期临床”译为未确定词的双语例句
     CONCLUSIONS: The MTD of rhLTα-Da is 33 μg·(m2·day)-1. The recommended dose for phase Ⅱ clinical trial is 20 μg·(m2·day)-1.
     结论:rhLTα-Da的MTD为33μg·(m·2d)-1,推荐Ⅱ期临床试验剂量为20μg·(m2·d)-1。
短句来源
     Report of phase Ⅱ clinical trial of APA-BCC_S
     APA-BCC_S镇痛微胶囊Ⅱ期临床研究报告
短句来源
     A phase Ⅰ clinical study of pharmaceutical C50 labeled with ~(131) I.
     导向治疗药物~(131)I-C50的Ⅰ期临床研究
短句来源
     METHODS: The dose escalation of rhLTα-Da was as follows:10 μg·(m2·day)-1, 20 μg·(m2·day)-1, and 33 μg·(m2·day)-1. Each group contained at least 3 patients.
     方法:剂量递增Ⅰ期临床试验。 rhLTα-Da剂量分3级,即10μg·(m·2d)-1、20μg·(m·2d)-1和33μg·(m·2d)-1,每剂量组至少有3例患者。
短句来源
     Study of Clinical Trial Ⅱ on 200 Cases Bearing MCu375(Ba)IUD
     含硫酸钡MCu375 IUD 200例Ⅱ期临床试验研究
短句来源
更多       
  相似匹配句对
     Injectio Artemetheri in Clinical Trial,Stage I
     蒿甲醚注射液I临床试验
短句来源
     A comparative analysis of clinical features of senile schizophrenia
     老年精神分裂症的临床特征
短句来源
查询“期临床”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  clinical phase
When tested in clinical phase I/II safety trials the recombinant lipOspA vaccine was shown to be safe, immunogenic and able to elicit borreliacidal antibodies.
      
At present, clinical phase III efficacy trials are being conducted.B.
      
Many clinical phase I/II evaluations in ILP are now underway.
      
The benefits and limitations of physical training programs and rehabilitation strategies depend on the clinical phase of the disease and analysis of underlying impairments responsible for functional limitations in the patient.
      
A subsequent clinical phase I study showed that an i.v.
      
更多          


Pseudolycorine is an alkaloid isolated from Narcissus tazetta var. chinensis Roem, N. papyraceus or Lycoris radiata Herb. Both the free alkaloid and its hydrochloride showed marked inhibition on the growth of W-256 carcinosarcoma in rats under tolerable doses, but the inhibition on the growth of hepatoma, subcutaneous transplants of Ehrlich ascites cascinoma and S-180 in mice was not significant. The LD_(50) of pseudolycorine injected intraperitoneally to rats was found to be 110(92.4~131)mg/kg. Intraveneous...

Pseudolycorine is an alkaloid isolated from Narcissus tazetta var. chinensis Roem, N. papyraceus or Lycoris radiata Herb. Both the free alkaloid and its hydrochloride showed marked inhibition on the growth of W-256 carcinosarcoma in rats under tolerable doses, but the inhibition on the growth of hepatoma, subcutaneous transplants of Ehrlich ascites cascinoma and S-180 in mice was not significant. The LD_(50) of pseudolycorine injected intraperitoneally to rats was found to be 110(92.4~131)mg/kg. Intraveneous infusion of the drug caused slow lowering of the blood pressure in the cat, but the dose of the drug required to kill the cat is rather high (av. 881mg/kg). The subacute toxicity tests in the dogs showed that pseudolycorine may induce nausea, vomiting and anorexia, but it did not inhibit the bone marrow significantly. Some increase of the nonprotein nitrogen value in the dogs after adminstration of the drug was observed, but this might be caused by prerenal factors. Autopsy of the dogs showed no significant pathological changes in the viscera, including the heart, liver, spleen, lung, kidney and intestine. Phase I clinical trial of the drug is now in progress.

伪石蒜硷是从石蒜科植物水仙及石蒜中提得的生物硷。其游离硷及盐酸盐在动物耐受剂量下,对大鼠W-256的生长有明显的抑制作用,抑制率在49~76%之间,统计学上差异非常显著。对小鼠肝癌、艾氏腹水癌皮下型、S-180的抑制作用不明显。已测得伪石蒜硷对大鼠一次腹腔注射的LD_(50)为110(92.4~131)mg/kg。对猫静脉滴注可致缓慢血压下降,滴注致死要求很大剂量(平均881mg/kg)。根据推算现在的病人试用剂量(~1mg/kg/日)是安全的。狗的亚急性毒性试验表明,此药可引起恶心、呕吐、厌食,但对骨髓无明显抑制作用。用药后曾见血中非蛋白氮值上升,考虑为肾前因素引起。病理解剖心、肝、脾、肺、肾、肠各脏器均未见明显病变。药物正开始进行Ⅰ期临床试用中。

In this paper the subacute toxicity of the new photosensitizer FSD-007 in dogs is reported. The manifestations of its subacute toxicity such as salivation, nausea, vomi-tus and other early syndromes were similar to those of porphyrinemia. The laboratory findings showed that the red cell system was depressed markedly, and hepatic and renal functions were impaired to some extent. These lesions were reversible and coincident with what was observed in its acute toxicity. The experimental results have further provided...

In this paper the subacute toxicity of the new photosensitizer FSD-007 in dogs is reported. The manifestations of its subacute toxicity such as salivation, nausea, vomi-tus and other early syndromes were similar to those of porphyrinemia. The laboratory findings showed that the red cell system was depressed markedly, and hepatic and renal functions were impaired to some extent. These lesions were reversible and coincident with what was observed in its acute toxicity. The experimental results have further provided the evidence that these may be used clinically fer guard against its toxic effects.The results of phase I of clinical pharmacological study of FSD-007 have shown that there were no toxic effects observed after 2.5-5.0mg/kg iv on condition that the patient were kept away from direct sunlight for a month. And its subacute toxieity test has demonstrated that all its toxic changes arc dose-related,reversible and predictable. This preparation, therefore, may be safely tested in phase II with same dosage, but no duplicate administration is permitted within two weeks.

本文报道肿瘤诊治新光敏剂PSD-007对狗的亚急性毒性。亚急性毒性的表现举如流涎、恶心、呕吐及其他早期症群与血卟啉病相似,实验室检查可见血液红系统的抑制,以及肝、肾功能的一定程度的损害,均属可逆反应,并与急性毒性相一致,进一步证实这些可作为PSD-007临床试用中的监护指标。 鉴于PSD-007第一期临床试验的结果表明,一次静注2.5~5.0mg/kg后在避免日光直接照射一个月的情况下,未出现包括光毒在内的任何毒副反应;而亚急性毒性试验又证实其毒性是可逆的,并与剂量平行,且可预测,故本制剂以相同剂量在不短于两周内重复给药可安全地开展第二期临床试验。

In order to clinically differentiate the pulmonary hypertention stage and the heart failure stage in infants with pneumonia, RPEP/RVET and RPEP/T were used as an objective standard for observing the clinical manifestations of these two stages. Many different clinical features were found which would help the physician to select a suitable time to use vasodilator drugs.

本文采用肺阻抗微分图时相分析法测量RPEP/RVET和RPEP/T两个比值以区别婴幼儿肺炎肺动脉高压期和心衰期。然后再以此两个比值作为客观指标观察心衰期及肺动脉高压期的临床表现,提出临床上的判断标准及何时需用血管扩张药。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关期临床的内容
在知识搜索中查有关期临床的内容
在数字搜索中查有关期临床的内容
在概念知识元中查有关期临床的内容
在学术趋势中查有关期临床的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社